Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Product Development

Lengthy TRPV1 pipeline now backed by Nobel prize

October 5, 2021 2:11 AM UTC

The now Nobel Prize-winning discovery of TRPV1 has led to a well-stocked therapeutic pipeline

The discovery that won UCSF Professor David Julius a Nobel Prize on Monday has led to a therapeutic pipeline containing at least 19 candidates and two marketed products, according to BioCentury’s BCIQ database.  

In the late 1990s, Julius identified and cloned a receptor responsible for encoding temperature sensation. The protein, called TRPV1, is involved in pain signaling and companies quickly recognized its potential for treating pain conditions...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article